BRPI1011129A2 - métodos e compostos inibidores de janus cinase - Google Patents
métodos e compostos inibidores de janus cinaseInfo
- Publication number
- BRPI1011129A2 BRPI1011129A2 BRPI1011129A BRPI1011129A BRPI1011129A2 BR PI1011129 A2 BRPI1011129 A2 BR PI1011129A2 BR PI1011129 A BRPI1011129 A BR PI1011129A BR PI1011129 A BRPI1011129 A BR PI1011129A BR PI1011129 A2 BRPI1011129 A2 BR PI1011129A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- kinase inhibitor
- janus kinase
- inhibitor methods
- methods
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18632209P | 2009-06-11 | 2009-06-11 | |
| PCT/EP2010/058128 WO2010142752A1 (en) | 2009-06-11 | 2010-06-10 | Janus kinase inhibitor compounds and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011129A2 true BRPI1011129A2 (pt) | 2016-11-01 |
Family
ID=42313557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011129A BRPI1011129A2 (pt) | 2009-06-11 | 2010-06-10 | métodos e compostos inibidores de janus cinase |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8486950B2 (pt) |
| EP (1) | EP2440529A1 (pt) |
| JP (1) | JP5763057B2 (pt) |
| KR (1) | KR101530117B1 (pt) |
| CN (1) | CN102459187B (pt) |
| AR (1) | AR077033A1 (pt) |
| AU (1) | AU2010258597B2 (pt) |
| BR (1) | BRPI1011129A2 (pt) |
| CA (1) | CA2764728A1 (pt) |
| IL (1) | IL216511A0 (pt) |
| MX (1) | MX2011012840A (pt) |
| SG (1) | SG176781A1 (pt) |
| TW (1) | TW201103904A (pt) |
| WO (1) | WO2010142752A1 (pt) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2774373A1 (en) * | 2009-09-17 | 2011-03-24 | Vanderbilt University | Substituted heteroarylamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US8354420B2 (en) | 2010-06-04 | 2013-01-15 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 inhibitors |
| SI2638031T1 (en) | 2010-11-10 | 2018-02-28 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as LRRK2 modulators |
| WO2012160464A1 (en) | 2011-05-26 | 2012-11-29 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
| WO2013018695A1 (ja) | 2011-07-29 | 2013-02-07 | 武田薬品工業株式会社 | 複素環化合物 |
| US9120776B2 (en) | 2011-09-22 | 2015-09-01 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| JPWO2013125543A1 (ja) | 2012-02-20 | 2015-07-30 | 武田薬品工業株式会社 | 複素環化合物 |
| EP2832734A4 (en) | 2012-03-28 | 2015-08-26 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND |
| BR112014026176A2 (pt) * | 2012-05-22 | 2017-06-27 | Hoffmann La Roche | dipiridilaminas substituídas e usos das mesmas |
| JPWO2013180265A1 (ja) | 2012-06-01 | 2016-01-21 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6372666B2 (ja) * | 2012-11-03 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | サイトメガロウイルスの阻害剤 |
| ES2857687T3 (es) | 2013-01-31 | 2021-09-29 | Vertex Pharma | Piridona amidas como moduladores de los canales de sodio |
| WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| AR094929A1 (es) * | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| JP6280912B2 (ja) | 2013-03-14 | 2018-02-14 | 武田薬品工業株式会社 | 複素環化合物 |
| ES2661012T3 (es) | 2013-03-28 | 2018-03-27 | Takeda Pharmaceutical Company Limited | Compuesto heterocíclico |
| WO2014177524A1 (en) | 2013-05-01 | 2014-11-06 | F. Hoffmann-La Roche Ag | C-linked heterocycloalkyl substituted pyrimidines and their uses |
| ES2950424T3 (es) | 2013-07-03 | 2023-10-09 | Takeda Pharmaceuticals Co | Compuesto de amida |
| WO2015002231A1 (ja) | 2013-07-03 | 2015-01-08 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3029031A4 (en) | 2013-07-30 | 2017-01-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3027590A1 (en) * | 2013-07-31 | 2016-06-08 | Minoryx Therapeutics S.L. | Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof |
| CA2925935A1 (en) | 2013-10-03 | 2015-04-09 | Millennium Pharmaceuticals, Inc. | Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis |
| AR094537A1 (es) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| WO2015068856A1 (en) | 2013-11-08 | 2015-05-14 | Takeda Pharmaceutical Company Limited | Pyrazole for the treatment autoimmune disorders |
| EP3071568A1 (en) | 2013-11-19 | 2016-09-28 | Vanderbilt University | Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5 |
| CA2931550C (en) | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| US9533982B2 (en) | 2014-03-20 | 2017-01-03 | Vanderbilt University | Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators |
| CN104926801B (zh) * | 2014-03-22 | 2019-06-04 | 浙江大学 | 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用 |
| CA2949785A1 (en) * | 2014-06-04 | 2015-12-10 | Thomas Helledays Stiftelse For Medicinsk Forskning | Mth1 inhibitors for treatment of cancer |
| WO2016028971A1 (en) * | 2014-08-21 | 2016-02-25 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| JP2017529393A (ja) | 2014-09-12 | 2017-10-05 | アンティバイオティクス エーピーエスＡｎｔｉｂｉｏｔｘ Ａｐｓ | ハロゲン化サリチルアニリドの抗菌用途 |
| US9550778B2 (en) | 2014-10-03 | 2017-01-24 | Vanderbilt University | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| WO2016199943A1 (en) | 2015-06-11 | 2016-12-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| CN108026088B (zh) | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
| WO2017014323A1 (en) | 2015-07-23 | 2017-01-26 | Takeda Pharmaceutical Company Limited | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists |
| GB201604484D0 (en) | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
| WO2018030550A1 (en) | 2016-08-09 | 2018-02-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds with an ror(gamma)t modulating activity |
| US11078165B2 (en) | 2017-02-15 | 2021-08-03 | Nanyang Technological University | Compounds for treating tuberculosis |
| EP3625214B1 (en) | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| WO2019157505A1 (en) | 2018-02-12 | 2019-08-15 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| WO2020100944A1 (ja) | 2018-11-14 | 2020-05-22 | 宇部興産株式会社 | ジヒドロピロロピラゾール誘導体 |
| WO2020117877A1 (en) * | 2018-12-04 | 2020-06-11 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
| PE20211475A1 (es) * | 2018-12-20 | 2021-08-05 | Amgen Inc | Inhibidores de kif18a |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2021018165A1 (zh) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| MX2022006865A (es) | 2019-12-06 | 2022-07-11 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN115298164A (zh) * | 2020-04-16 | 2022-11-04 | 巴斯夫欧洲公司 | 制备4-氰基苯甲酰氯的方法 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| WO2022063140A1 (en) * | 2020-09-23 | 2022-03-31 | Shenzhen Ionova Life Science Co., Ltd. | Pyrimidine and pyridine derivatives as hpk1 modulator and methods using same |
| CN117396469A (zh) * | 2021-03-17 | 2024-01-12 | 武田药品工业株式会社 | 血浆激肽释放酶的抑制剂 |
| CN117794920A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂 |
| WO2023028564A1 (en) | 2021-08-26 | 2023-03-02 | Volastra Therapeutics, Inc. | Spiro indoline inhibitors of kif18a |
| CN116789642A (zh) * | 2022-03-18 | 2023-09-22 | 华东师范大学 | 一类诱导肿瘤细胞发生methuosis死亡的三芳香杂环哌嗪类化合物及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3317534A (en) * | 1963-10-30 | 1967-05-02 | Chugai Pharmaceutical Co Ltd | Benzamidopyrimidines |
| JPS62158252A (ja) * | 1985-12-28 | 1987-07-14 | Kirin Brewery Co Ltd | ４−アミノピリジンベンズアミド誘導体 |
| DE4127404A1 (de) * | 1991-08-19 | 1993-02-25 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| ES2176251T3 (es) * | 1993-07-28 | 2002-12-01 | Aventis Pharma Ltd | Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf). |
| EP1195372A1 (en) * | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JP3057763B2 (ja) * | 1995-06-06 | 2000-07-04 | ヘキスト・マリオン・ルセル・インコーポレイテツド | 抗精神病薬としてのベンゾイソオキサゾール及びインダゾール誘導体 |
| JPH111456A (ja) * | 1997-06-13 | 1999-01-06 | Otsuka Pharmaceut Co Ltd | アミド誘導体 |
| US6562844B2 (en) * | 1998-01-23 | 2003-05-13 | Pharmacia & Upjohn Company | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
| DE10021246A1 (de) | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
| MXPA02010651A (es) * | 2000-04-28 | 2003-03-10 | Sankyo Co | Moduladores de receptor activado de proliferador de peroxisoma-gamma. |
| US20040102324A1 (en) | 2002-02-28 | 2004-05-27 | Annis Gary David | Heterocyclic diamide invertebrate pest control agents |
| WO2002076918A1 (fr) * | 2001-03-27 | 2002-10-03 | Suntory Limited | Inhibiteur nf-kb contenant comme principe actif un derive d'acide benzoique substitue |
| JP2003073357A (ja) * | 2001-09-03 | 2003-03-12 | Mitsubishi Pharma Corp | アミド化合物を含有するＲｈｏキナーゼ阻害剤 |
| ATE360015T1 (de) * | 2002-07-31 | 2007-05-15 | Critical Outcome Technologies | Protein tyrosin kinase inhibitoren |
| WO2005032493A2 (en) * | 2003-10-07 | 2005-04-14 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
| GB0403635D0 (en) | 2004-02-18 | 2004-03-24 | Devgen Nv | Pyridinocarboxamides with improved activity as kinase inhibitors |
| US7102002B2 (en) * | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2006040645A1 (en) * | 2004-10-11 | 2006-04-20 | Ranbaxy Laboratories Limited | N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma |
| DE602005010744D1 (de) | 2004-12-16 | 2008-12-11 | Hoffmann La Roche | Piperazinylpyridinderivate als mittel gegen adipositas |
| MX2007007574A (es) | 2004-12-22 | 2007-07-24 | Astrazeneca Ab | Derivados de piridina-carboxamida para uso como agentes anticancerosos. |
| US20060247250A1 (en) | 2005-03-16 | 2006-11-02 | Targegen, Inc. | Pyrimidine inhibitors of kinases |
| DE102005060449A1 (de) * | 2005-12-17 | 2007-06-21 | Bayer Cropscience Ag | Carboxamide |
| KR20080110998A (ko) | 2006-01-30 | 2008-12-22 | 엑셀리시스, 인코포레이티드 | Ｊａｋ２ 조절자로서 ４아릴２아미노피리미딘 또는 4아릴２아미노알킬피리미딘 및 이들을 포함하는 약제학적 조성물 |
| ES2604542T3 (es) * | 2006-06-29 | 2017-03-07 | F. Hoffmann-La Roche Ag | Arilamidas con sustitución tetrazol |
| PT2049556E (pt) * | 2006-08-09 | 2013-08-22 | Basilea Pharmaceutica Ag | Novos macrólidos úteis contra doenças inflamatórias e alérgicas |
| WO2008044700A1 (en) * | 2006-10-11 | 2008-04-17 | Takeda Pharmaceutical Company Limited | GSK-3β INHIBITOR |
| EP2049483A2 (en) | 2006-10-28 | 2009-04-22 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| WO2008112695A2 (en) * | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
| JP5559043B2 (ja) * | 2007-06-07 | 2014-07-23 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 新規ヘテロ環化合物およびその使用 |
| US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| US7982036B2 (en) | 2007-10-19 | 2011-07-19 | Avila Therapeutics, Inc. | 4,6-disubstitued pyrimidines useful as kinase inhibitors |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
-
2010
- 2010-06-09 TW TW099118786A patent/TW201103904A/zh unknown
- 2010-06-09 AR ARP100102023A patent/AR077033A1/es unknown
- 2010-06-10 CA CA2764728A patent/CA2764728A1/en not_active Abandoned
- 2010-06-10 AU AU2010258597A patent/AU2010258597B2/en not_active Expired - Fee Related
- 2010-06-10 EP EP10721178A patent/EP2440529A1/en not_active Withdrawn
- 2010-06-10 KR KR1020127000759A patent/KR101530117B1/ko not_active Expired - Fee Related
- 2010-06-10 US US12/813,142 patent/US8486950B2/en not_active Expired - Fee Related
- 2010-06-10 BR BRPI1011129A patent/BRPI1011129A2/pt not_active IP Right Cessation
- 2010-06-10 CN CN201080025358.XA patent/CN102459187B/zh not_active Expired - Fee Related
- 2010-06-10 MX MX2011012840A patent/MX2011012840A/es active IP Right Grant
- 2010-06-10 SG SG2011091451A patent/SG176781A1/en unknown
- 2010-06-10 WO PCT/EP2010/058128 patent/WO2010142752A1/en not_active Ceased
- 2010-06-10 JP JP2012514472A patent/JP5763057B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-21 IL IL216511A patent/IL216511A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011012840A (es) | 2012-01-27 |
| AU2010258597B2 (en) | 2016-02-25 |
| AU2010258597A1 (en) | 2011-12-15 |
| US20100317643A1 (en) | 2010-12-16 |
| IL216511A0 (en) | 2012-02-29 |
| SG176781A1 (en) | 2012-01-30 |
| CA2764728A1 (en) | 2010-12-16 |
| US8486950B2 (en) | 2013-07-16 |
| KR101530117B1 (ko) | 2015-06-18 |
| WO2010142752A1 (en) | 2010-12-16 |
| KR20120034729A (ko) | 2012-04-12 |
| CN102459187A (zh) | 2012-05-16 |
| CN102459187B (zh) | 2015-06-17 |
| AR077033A1 (es) | 2011-07-27 |
| JP5763057B2 (ja) | 2015-08-12 |
| EP2440529A1 (en) | 2012-04-18 |
| JP2012529470A (ja) | 2012-11-22 |
| TW201103904A (en) | 2011-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1006I2 (fr) | Inhibiteurs de pyrazolyl-quinoxaline kinase | |
| CY2020024I1 (el) | Αναστολεiς βητα-λακταμασων | |
| HUS1900029I1 (hu) | Kináz inhibitor foszforszármazékok | |
| IL216511A0 (en) | Janus kinase inhibitor compounds and methods | |
| BRPI0820544A2 (pt) | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase | |
| CY2017016I1 (el) | Αναστολεις πρωτεασωματος | |
| EP2278969A4 (en) | JANUS KINASE INHIBITORS | |
| ATE522535T1 (de) | Pyrrolotriazin-kinasehemmer | |
| EP2299816A4 (en) | JANUS KINASE INHIBITORS | |
| BRPI0922880A2 (pt) | compostos inibidores de quinase | |
| EP2231143A4 (en) | JANUS KINASE INHIBITORS | |
| EP2498607A4 (en) | Kinase Inhibitors | |
| EP2493313A4 (en) | Kinase Inhibitors | |
| EP2305306A4 (en) | NEURO INVASION INHIBITOR | |
| BRPI0918846A2 (pt) | inibidores de cinase heterocíclica | |
| EP2421867A4 (en) | PIPERIDINIC INHIBITORS OF JANUS KINASE 3 | |
| BRPI1009112A2 (pt) | inibidores de tirosina quinase de bruton | |
| ATE519763T1 (de) | Pyrrolopyrazin-kinasehemmer | |
| EP2558099A4 (en) | Kinase inhibitors | |
| EP2166846A4 (en) | JANUS KINASE INHIBITORS | |
| BRPI0917808A2 (pt) | inibidores de cmet | |
| BRPI0922937A2 (pt) | inibidores de pirrolopirazinil uréia quinase | |
| BRPI0910668A2 (pt) | inibidores de proteína quinases | |
| CR10831A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
| BRPI0918564A2 (pt) | inibidores |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |